POLR2A

Across TCGA pan-cancer cohorts, POLR2A mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of POLR2A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where POLR2A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types POLR2A is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

HNSC, PDAC, and LSCC are the cancer types where POLR2A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in POLR2A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	II,III,IV	+0.245	<.001	11	view →
PDAC	Male	II,III,IV	−0.303	<.001	8	view →
LSCC	Male	All	+0.278	<.001	8	view →
LUAD	Male	All	+0.109	<.001	6	view →
CCRCC	Male	All	+0.094	<.001	6	view →
COAD	All	II,III,IV	+0.077	.002	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

POLR2A–HNSC

Open the HNSC breakdown →